Aduro Biotech Boss Isaacs Outlines Immunotherapy Clinical Plans
Executive Summary
Aduro Biotech has enough cash runway to take it through the end of 2020. Its chairman, president and CEO spoke to Scrip about how the company plans to spend it developing its three core immunotherapy platforms.